These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35159960)

  • 1. Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Onishi S; Tajika M; Tanaka T; Yamada K; Kamiya T; Abe T; Higaki E; Fujieda H; Nagao T; Inaba Y; Muro K; Shimizu M; Niwa Y
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35159960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal muscle mass and quality before preoperative chemotherapy influence postoperative long-term outcomes in esophageal squamous cell carcinoma patients.
    Ichinohe D; Muroya T; Akasaka H; Hakamada K
    World J Gastrointest Surg; 2023 Apr; 15(4):621-633. PubMed ID: 37206067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
    Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
    Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
    Yip C; Goh V; Davies A; Gossage J; Mitchell-Hay R; Hynes O; Maisey N; Ross P; Gaya A; Landau DB; Cook GJ; Griffin N; Mason R
    Eur Radiol; 2014 May; 24(5):998-1005. PubMed ID: 24535076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
    Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
    Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal Muscle Quality and Quantity Affect Prognosis after Neoadjuvant Chemotherapy with a Triple Regimen of Docetaxel/Cisplatin/5-FU in Patients with Esophageal Cancer.
    Ito N; Tajika M; Tanaka T; Yamada K; Takagi A; Onishi S; Abe T; Higaki E; Fujieda H; Inaba Y; Muro K; Kawashima H; Niwa Y
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
    Miyata H; Sugimura K; Motoori M; Fujiwara Y; Omori T; Yanagimoto Y; Ohue M; Yasui M; Miyoshi N; Tomokuni A; Akita H; Kobayashi S; Takahashi H; Yano M
    Anticancer Res; 2017 Jun; 37(6):3053-3059. PubMed ID: 28551644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Prognostic Nutritional Index in the Treatment of Esophageal Squamous Cell Carcinoma.
    Takao K; Konishi H; Fujiwara H; Shiozaki A; Shoda K; Kosuga T; Kubota T; Arita T; Morimura R; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Okamoto K; Otsuji E
    In Vivo; 2020; 34(6):3451-3457. PubMed ID: 33144453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
    Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
    World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
    Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
    Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.
    Ueki S; Fujishima F; Kumagai T; Ishida H; Okamoto H; Takaya K; Sato C; Taniyma Y; Kamei T; Sasano H
    BMC Cancer; 2020 Feb; 20(1):161. PubMed ID: 32106831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma.
    Onishi S; Tajika M; Tanaka T; Yamada K; Abe T; Higaki E; Hosoi T; Inaba Y; Muro K; Shimizu M; Niwa Y
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32942595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
    Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
    Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer.
    Otowa Y; Nakamura T; Yamamoto M; Kanaji S; Matsuda Y; Matsuda T; Oshikiri T; Sumi Y; Suzuki S; Kakeji Y
    Dis Esophagus; 2017 Dec; 30(12):1-5. PubMed ID: 28881893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
    Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
    Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma.
    Ozeki N; Kawaguchi K; Fukui T; Nakamura S; Hakiri S; Mori S; Goto M; Iwano S; Yokoi K; Chen-Yoshikawa TF
    Int J Clin Oncol; 2020 May; 25(5):876-884. PubMed ID: 31955305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.